{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:47:46Z","timestamp":1792799266822,"version":"4.5.0"},"reference-count":151,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T00:00:00Z","timestamp":1738627200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T00:00:00Z","timestamp":1738627200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Endocrinol"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1038\/s41574-024-01075-8","type":"journal-article","created":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T19:13:26Z","timestamp":1738696406000},"page":"360-374","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["Hypoparathyroidism: diagnosis, management and emerging therapies"],"prefix":"10.1038","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3604-303X","authenticated-orcid":false,"given":"Sarah","family":"Khan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aliya A.","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,4]]},"reference":[{"key":"1075_CR1","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1002\/jbmr.4714","volume":"37","author":"JL Pasieka","year":"2022","unstructured":"Pasieka, J. L. et al. Etiology and pathophysiology of hypoparathyroidism: a narrative review. J. Bone Miner. Res. 37, 2586\u20132601 (2022). An excellent review of the various causes of hypoparathyroidism.","journal-title":"J. Bone Miner. Res."},{"key":"1075_CR2","doi-asserted-by":"crossref","first-page":"2602","DOI":"10.1002\/jbmr.4675","volume":"37","author":"S Bjornsdottir","year":"2022","unstructured":"Bjornsdottir, S. et al. Epidemiology and financial burden of adult chronic hypoparathyroidism. J. Bone Miner. Res. 37, 2602\u20132614 (2022).","journal-title":"J. Bone Miner. Res."},{"key":"1075_CR3","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1002\/jbmr.4691","volume":"37","author":"AA Khan","year":"2022","unstructured":"Khan, A. A. et al. Evaluation and management of hypoparathyroidism summary statement and guidelines from the second international workshop. J. Bone Miner. Res. 37, 2568\u20132585 (2022). The summary statement of the 2022 guidelines on hypoparathyroidism.","journal-title":"J. Bone Miner. Res."},{"key":"1075_CR4","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1210\/jc.2015-3907","volume":"101","author":"ML Brandi","year":"2016","unstructured":"Brandi, M. L. et al. Management of hypoparathyroidism: summary statement and guidelines. J. Clin. Endocrinol. Metab. 101, 2273\u20132283 (2016).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1075_CR5","doi-asserted-by":"crossref","first-page":"17055","DOI":"10.1038\/nrdp.2017.55","volume":"3","author":"M Mannstadt","year":"2017","unstructured":"Mannstadt, M. et al. Hypoparathyroidism. Nat. Rev. Dis. Prim. 3, 17055 (2017).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"1075_CR6","doi-asserted-by":"crossref","first-page":"e2215","DOI":"10.1210\/clinem\/dgab038","volume":"106","author":"G Puliani","year":"2021","unstructured":"Puliani, G. et al. Impaired immune function in patients with chronic postsurgical hypoparathyroidism: results of the EMPATHY study. J. Clin. Endocrinol. Metab. 106, e2215\u2013e2227 (2021).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1075_CR7","doi-asserted-by":"crossref","first-page":"262","DOI":"10.3803\/EnM.2024.1916","volume":"39","author":"L Rejnmark","year":"2024","unstructured":"Rejnmark, L. Treatment of hypoparathyroidism by re-establishing the effects of parathyroid hormone. Endocrinol. Metab. 39, 262\u2013266 (2024).","journal-title":"Endocrinol. Metab."},{"key":"1075_CR8","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.jpeds.2014.04.060","volume":"165","author":"KK Winer","year":"2014","unstructured":"Winer, K. K., Fulton, K. A., Albert, P. S. & Cutler, G. B. Jr. Effects of pump versus twice-daily injection delivery of synthetic parathyroid hormone 1-34 in children with severe congenital hypoparathyroidism. J. Pediatr. 165, 556\u2013563.e1 (2014).","journal-title":"J. Pediatr."},{"key":"1075_CR9","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.jpeds.2018.08.010","volume":"203","author":"KK Winer","year":"2018","unstructured":"Winer, K. K. et al. Long-term parathyroid hormone 1-34 replacement therapy in children with hypoparathyroidism. J. Pediatr. 203, 391\u2013399.e1 (2018).","journal-title":"J. Pediatr."},{"key":"1075_CR10","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1210\/jc.2007-2552","volume":"93","author":"KK Winer","year":"2008","unstructured":"Winer, K. K. et al. Effects of once versus twice-daily parathyroid hormone 1-34 therapy in children with hypoparathyroidism. J. Clin. Endocrinol. Metab. 93, 3389\u20133395 (2008).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1075_CR11","first-page":"3480","volume":"83","author":"KK Winer","year":"1998","unstructured":"Winer, K. K., Yanovski, J. A., Sarani, B. & Cutler, G. B. Jr. A randomized, cross-over trial of once-daily versus twice-daily parathyroid hormone 1-34 in treatment of hypoparathyroidism. J. Clin. Endocrinol. Metab. 83, 3480\u20133486 (1998).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1075_CR12","first-page":"391","volume":"97","author":"KK Winer","year":"2012","unstructured":"Winer, K. K. et al. Synthetic human parathyroid hormone 1-34 replacement therapy: a randomized crossover trial comparing pump versus injections in the treatment of chronic hypoparathyroidism. J. Clin. Endocrinol. Metab. 97, 391\u2013399 (2012).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1075_CR13","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S2213-8587(13)70106-2","volume":"1","author":"M Mannstadt","year":"2013","unstructured":"Mannstadt, M. et al. Efficacy and safety of recombinant human parathyroid hormone (1-84) in hypoparathyroidism (REPLACE): a double-blind, placebo-controlled, randomised, phase 3 study. Lancet Diabetes Endocrinol. 1, 275\u2013283 (2013). A landmark trial for the use of PTH (1\u201384) in patients with hypoparathyroidism.","journal-title":"Lancet Diabetes Endocrinol."},{"key":"1075_CR14","doi-asserted-by":"crossref","first-page":"5601","DOI":"10.1210\/jc.2019-00893","volume":"104","author":"YD Tay","year":"2019","unstructured":"Tay, Y. D. et al. Therapy of hypoparathyroidism with rhPTH(1-84): a prospective, 8-year investigation of efficacy and safety. J. Clin. Endocrinol. Metab. 104, 5601\u20135610 (2019).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1075_CR15","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1002\/jbmr.470","volume":"26","author":"T Sikjaer","year":"2011","unstructured":"Sikjaer, T., Rejnmark, L., Rolighed, L., Heickendorff, L. & Mosekilde, L. The effect of adding PTH(1-84) to conventional treatment of hypoparathyroidism: a randomized, placebo-controlled study. J. Bone Miner. Res. 26, 2358\u20132370 (2011).","journal-title":"J. Bone Miner. Res."},{"key":"1075_CR16","unstructured":"US Food and Drug Administration. FDA approves new drug for hypoparathyroidism, a rare disorder. FDA.gov https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-new-drug-hypoparathyroidism-rare-disorder (2024)."},{"key":"1075_CR17","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1210\/clinem\/dgae121","volume":"109","author":"I Takacs","year":"2024","unstructured":"Takacs, I. et al. An open-label phase 2 study of eneboparatide, a novel PTH receptor 1 agonist, in hypoparathyroidism. J. Clin. Endocrinol. Metab. 109, 2199\u20132209 (2024). The most recent study on eneboparatide, an emerging treatment for hypoparathyroidism.","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1075_CR18","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1056\/NEJMc2302708","volume":"389","author":"RI Gafni","year":"2023","unstructured":"Gafni, R. I. et al. Efficacy and safety of encaleret in autosomal dominant hypocalcemia type 1. N. Engl. J. Med. 389, 1245\u20131247 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1075_CR19","doi-asserted-by":"publisher","unstructured":"Carney, P., Cutler, G. B. Jr, Schneider, K., Zhang, F. & DiMarchi, R. MBX 2109, a once-weekly parathyroid hormone replacement therapy prodrug: phase 1, first-in-human, randomized trial. J. Clin. Endocrinol. Metab. https:\/\/doi.org\/10.1210\/clinem\/dgae808 (2024).","DOI":"10.1210\/clinem\/dgae808"},{"key":"1075_CR20","doi-asserted-by":"crossref","first-page":"bvae163.386","DOI":"10.1210\/jendso\/bvae163.386","volume":"8","author":"J Zhang","year":"2024","unstructured":"Zhang, J. et al. 6821 Characterization of a novel oral small molecule PTH1R agonist: proof of concept for an alternative to injectable peptide-based therapy for hypoparathyroidism. J. Endocrine Soc. 8, bvae163.386 (2024).","journal-title":"J. Endocrine Soc."},{"key":"1075_CR21","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/jbmr.4274","volume":"36","author":"S Ish-Shalom","year":"2021","unstructured":"Ish-Shalom, S. et al. Safety and efficacy of oral human parathyroid hormone (1-34) in hypoparathyroidism: an open-label study. J. Bone Miner. Res. 36, 1060\u20131068 (2021).","journal-title":"J. Bone Miner. Res."},{"key":"1075_CR22","doi-asserted-by":"crossref","first-page":"543","DOI":"10.3390\/jcm10030543","volume":"10","author":"A Sitges-Serra","year":"2021","unstructured":"Sitges-Serra, A. Etiology and diagnosis of permanent hypoparathyroidism after total thyroidectomy. J. Clin. Med. 10, 543 (2021).","journal-title":"J. Clin. Med."},{"key":"1075_CR23","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1210\/clinem\/dgaa113","volume":"105","author":"JP Bilezikian","year":"2020","unstructured":"Bilezikian, J. P. Hypoparathyroidism. J. Clin. Endocrinol. Metab. 105, 1722\u20131736 (2020).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1075_CR24","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1002\/jbmr.4667","volume":"37","author":"M Mannstadt","year":"2022","unstructured":"Mannstadt, M. et al. Hypoparathyroidism: genetics and diagnosis. J. Bone Miner. Res. 37, 2615\u20132629 (2022). An important review of the various genetic causes of hypoparathyroidism and guidelines for diagnosis.","journal-title":"J. Bone Miner. Res."},{"key":"1075_CR25","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1002\/jbmr.2004","volume":"28","author":"J Powers","year":"2013","unstructured":"Powers, J., Joy, K., Ruscio, A. & Lagast, H. Prevalence and incidence of hypoparathyroidism in the United States using a large claims database. J. Bone Miner. Res. 28, 2570\u20132576 (2013).","journal-title":"J. Bone Miner. Res."},{"key":"1075_CR26","first-page":"82","volume":"4","author":"L Lorente-Poch","year":"2015","unstructured":"Lorente-Poch, L., Sancho, J. J., Mu\u00f1oz-Nova, J. L., S\u00e1nchez-Vel\u00e1zquez, P. & Sitges-Serra, A. Defining the syndromes of parathyroid failure after total thyroidectomy. Gland. Surg. 4, 82\u201390 (2015).","journal-title":"Gland. Surg."},{"key":"1075_CR27","doi-asserted-by":"crossref","first-page":"17","DOI":"10.5005\/jp-journals-10002-1015","volume":"2","author":"W Jessie","year":"2010","unstructured":"Jessie, W., & Harrison, B. Hypocalcemia after thyroidectomy: the need for improved definitions. World J. Endocr. Surg. 2, 17\u201320 (2010).","journal-title":"World J. Endocr. Surg."},{"key":"1075_CR28","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/hed.21175","volume":"32","author":"HM Mehanna","year":"2010","unstructured":"Mehanna, H. M., Jain, A., Randeva, H., Watkinson, J. & Shaha, A. Postoperative hypocalcemia-the difference a definition makes. Head Neck 32, 279\u2013283 (2010).","journal-title":"Head Neck"},{"key":"1075_CR29","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/bjs.9384","volume":"101","author":"O Edafe","year":"2014","unstructured":"Edafe, O., Antakia, R., Laskar, N., Uttley, L. & Balasubramanian, S. P. Systematic review and meta-analysis of predictors of post-thyroidectomy hypocalcaemia. Br. J. Surg. 101, 307\u2013320 (2014).","journal-title":"Br. J. Surg."},{"key":"1075_CR30","volume":"13","author":"B Bai","year":"2018","unstructured":"Bai, B., Chen, Z. & Chen, W. Risk factors and outcomes of incidental parathyroidectomy in thyroidectomy: a systematic review and meta-analysis. PLoS ONE\u00a013, e0207088 (2018).","journal-title":"PLoS ONE"},{"key":"1075_CR31","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/j.surg.2020.11.023","volume":"169","author":"L Barrios","year":"2021","unstructured":"Barrios, L. et al. Incidental parathyroidectomy in thyroidectomy and central neck dissection. Surgery 169, 1145\u20131151 (2021).","journal-title":"Surgery"},{"key":"1075_CR32","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.ecl.2018.07.006","volume":"47","author":"N Siraj","year":"2018","unstructured":"Siraj, N., Hakami, Y. & Khan, A. Medical hypoparathyroidism. Endocrinol. Metab. Clin. North Am. 47, 797\u2013808 (2018).","journal-title":"Endocrinol. Metab. Clin. North Am."},{"key":"1075_CR33","doi-asserted-by":"crossref","first-page":"4602","DOI":"10.1210\/jc.2003-030700","volume":"88","author":"M Gylling","year":"2003","unstructured":"Gylling, M. et al. The hypoparathyroidism of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy protective effect of male sex. J. Clin. Endocrinol. Metab. 88, 4602\u20134608 (2003).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1075_CR34","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1055\/s-0029-1233535","volume":"29","author":"TO Lankisch","year":"2009","unstructured":"Lankisch, T. O., Jaeckel, E. & Strassburg, C. P. The autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy or autoimmune polyglandular syndrome type 1. Semin. Liver Dis. 29, 307\u2013314 (2009).","journal-title":"Semin. Liver Dis."},{"key":"1075_CR35","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/ng1297-399","volume":"17","author":"J Aaltonen","year":"1997","unstructured":"Aaltonen, J. et al. An autoimmune disease, APECED, caused by mutations in a novel gene featuring two PHD-type zinc-finger domains. Nat. Genet. 17, 399\u2013403 (1997).","journal-title":"Nat. Genet."},{"key":"1075_CR36","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMra1713301","volume":"378","author":"ES Husebye","year":"2018","unstructured":"Husebye, E. S., Anderson, M. S. & K\u00e4mpe, O. Autoimmune polyendocrine syndromes. N. Engl. J. Med. 378, 1132\u20131141 (2018).","journal-title":"N. Engl. J. Med."},{"key":"1075_CR37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1530\/EJE-18-0609","volume":"180","author":"AA Khan","year":"2019","unstructured":"Khan, A. A. et al. Standards of care for hypoparathyroidism in adults: a Canadian and International Consensus. Eur. J. Endocrinol. 180, 1\u201322 (2019).","journal-title":"Eur. J. Endocrinol."},{"key":"1075_CR38","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1172\/JCI118513","volume":"97","author":"Y Li","year":"1996","unstructured":"Li, Y. et al. Autoantibodies to the extracellular domain of the calcium sensing receptor in patients with acquired hypoparathyroidism. J. Clin. Invest. 97, 910\u2013914 (1996).","journal-title":"J. Clin. Invest."},{"key":"1075_CR39","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1530\/eje.0.1500009","volume":"150","author":"R Goswami","year":"2004","unstructured":"Goswami, R. et al. Prevalence of calcium sensing receptor autoantibodies in patients with sporadic idiopathic hypoparathyroidism. Eur. J. Endocrinol. 150, 9\u201318 (2004).","journal-title":"Eur. J. Endocrinol."},{"key":"1075_CR40","doi-asserted-by":"crossref","first-page":"4749","DOI":"10.1210\/jc.2009-1080","volume":"94","author":"EH Kemp","year":"2009","unstructured":"Kemp, E. H. et al. Activating autoantibodies against the calcium-sensing receptor detected in two patients with autoimmune polyendocrine syndrome type 1. J. Clin. Endocrinol. Metab. 94, 4749\u20134756 (2009).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1075_CR41","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.ecl.2009.01.001","volume":"38","author":"EM Brown","year":"2009","unstructured":"Brown, E. M. Anti-parathyroid and anti-calcium sensing receptor antibodies in autoimmune hypoparathyroidism. Endocrinol. Metab. Clin. North Am. 38, 437\u2013445 (2009).","journal-title":"Endocrinol. Metab. Clin. North Am."},{"key":"1075_CR42","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1210\/jc.2015-3908","volume":"101","author":"BL Clarke","year":"2016","unstructured":"Clarke, B. L. et al. Epidemiology and diagnosis of hypoparathyroidism. J. Clin. Endocrinol. Metab. 101, 2284\u20132299 (2016).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1075_CR43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MD.0b013e3182060469","volume":"90","author":"DM McDonald-McGinn","year":"2011","unstructured":"McDonald-McGinn, D. M. & Sullivan, K. E. Chromosome 22q11.2 deletion syndrome (DiGeorge syndrome\/velocardiofacial syndrome). Medicine 90, 1\u201318 (2011).","journal-title":"Medicine"},{"key":"1075_CR44","first-page":"1","volume":"3","author":"R Hong","year":"1991","unstructured":"Hong, R. The DiGeorge anomaly. Immunodefic. Rev. 3, 1\u201314 (1991).","journal-title":"Immunodefic. Rev."},{"key":"1075_CR45","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2021-245164","volume":"15","author":"E Altshuler","year":"2022","unstructured":"Altshuler, E., Saidi, A. & Budd, J. DiGeorge syndrome: consider the diagnosis. BMJ Case Rep. 15, e245164 (2022).","journal-title":"BMJ Case Rep."},{"key":"1075_CR46","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/cen.12466","volume":"81","author":"EN Cheung","year":"2014","unstructured":"Cheung, E. N. et al. Prevalence of hypocalcaemia and its associated features in 22q11\u00b72 deletion syndrome. Clin. Endocrinol. 81, 190\u2013196 (2014).","journal-title":"Clin. Endocrinol."},{"key":"1075_CR47","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1136\/jcp.2004.023218","volume":"58","author":"PS Kar","year":"2005","unstructured":"Kar, P. S., Ogoe, B., Poole, R. & Meeking, D. Di-George syndrome presenting with hypocalcaemia in adulthood: two case reports and a review. J. Clin. Pathol. 58, 655\u2013657 (2005).","journal-title":"J. Clin. Pathol."},{"key":"1075_CR48","doi-asserted-by":"crossref","DOI":"10.1038\/srep40031","volume":"7","author":"L Verg\u00e9s","year":"2017","unstructured":"Verg\u00e9s, L. et al. An exploratory study of predisposing genetic factors for DiGeorge\/velocardiofacial syndrome. Sci. Rep. 7, 40031 (2017).","journal-title":"Sci. Rep."},{"key":"1075_CR49","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s11882-013-0384-6","volume":"13","author":"S Gao","year":"2013","unstructured":"Gao, S., Li, X. & Amendt, B. A. Understanding the role of Tbx1 as a candidate gene for 22q11.2 deletion syndrome. Curr. Allergy Asthma Rep. 13, 613\u2013621 (2013).","journal-title":"Curr. Allergy Asthma Rep."},{"key":"1075_CR50","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1203\/01.pdr.0000218420.00525.98","volume":"59","author":"AM Moon","year":"2006","unstructured":"Moon, A. M. Mouse models for investigating the developmental basis of human birth defects. Pediatr. Res. 59, 749\u2013755 (2006).","journal-title":"Pediatr. Res."},{"key":"1075_CR51","doi-asserted-by":"crossref","first-page":"7729","DOI":"10.1073\/pnas.0600206103","volume":"103","author":"R Paylor","year":"2006","unstructured":"Paylor, R. et al. Tbx1 haploinsufficiency is linked to behavioral disorders in mice and humans: implications for 22q11 deletion syndrome. Proc. Natl Acad. Sci. USA 103, 7729\u20137734 (2006).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1075_CR52","doi-asserted-by":"crossref","first-page":"e871","DOI":"10.1542\/peds.2008-3400","volume":"123","author":"S Jyonouchi","year":"2009","unstructured":"Jyonouchi, S., McDonald-McGinn, D. M., Bale, S., Zackai, E. H. & Sullivan, K. E. CHARGE (coloboma, heart defect, atresia choanae, retarded growth and development, genital hypoplasia, ear anomalies\/deafness) syndrome and chromosome 22q11.2 deletion syndrome: a comparison of immunologic and nonimmunologic phenotypic features. Pediatrics 123, e871\u2013e877 (2009).","journal-title":"Pediatrics"},{"key":"1075_CR53","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1399-0004.2008.01014.x","volume":"74","author":"J Wincent","year":"2008","unstructured":"Wincent, J. et al. CHD7 mutation spectrum in 28 Swedish patients diagnosed with CHARGE syndrome. Clin. Genet. 74, 31\u201338 (2008).","journal-title":"Clin. Genet."},{"key":"1075_CR54","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1002\/ajmg.a.38693","volume":"176","author":"AJ Barakat","year":"2018","unstructured":"Barakat, A. J., Raygada, M. & Rennert, O. M. Barakat syndrome revisited. Am. J. Med. Genet. A 176, 1341\u20131348 (2018).","journal-title":"Am. J. Med. Genet. A"},{"key":"1075_CR55","doi-asserted-by":"crossref","DOI":"10.1017\/erm.2016.2","volume":"18","author":"MH Lentjes","year":"2016","unstructured":"Lentjes, M. H. et al. The emerging role of GATA transcription factors in development and disease. Expert Rev. Mol. Med. 18, e3 (2016).","journal-title":"Expert Rev. Mol. Med."},{"key":"1075_CR56","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.4158\/EP13050.RA","volume":"19","author":"J Upadhyay","year":"2013","unstructured":"Upadhyay, J., Steenkamp, D. W. & Milunsky, J. M. The syndrome of hypoparathyroidism, deafness, and renal anomalies. Endocr. Pract. 19, 1035\u20131042 (2013).","journal-title":"Endocr. Pract."},{"key":"1075_CR57","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/ng1012","volume":"32","author":"R Parvari","year":"2002","unstructured":"Parvari, R. et al. Mutation of TBCE causes hypoparathyroidism-retardation-dysmorphism and autosomal recessive Kenny-Caffey syndrome. Nat. Genet. 32, 448\u2013452 (2002).","journal-title":"Nat. Genet."},{"key":"1075_CR58","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1136\/jmg.37.1.63","volume":"37","author":"TE Kelly","year":"2000","unstructured":"Kelly, T. E., Blanton, S., Saif, R., Sanjad, S. A. & Sakati, N. A. Confirmation of the assignment of the Sanjad-Sakati (congenital hypoparathyroidism) syndrome (OMIM 241410) locus to chromosome lq42-43. J. Med. Genet. 37, 63\u201364 (2000).","journal-title":"J. Med. Genet."},{"key":"1075_CR59","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1002\/jbmr.4659","volume":"37","author":"KL Roszko","year":"2022","unstructured":"Roszko, K. L. et al. Autosomal dominant hypocalcemia type 1: a systematic review. J. Bone Miner. Res. 37, 1926\u20131935 (2022).","journal-title":"J. Bone Miner. Res."},{"key":"1075_CR60","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1093\/hmg\/5.5.601","volume":"5","author":"J Baron","year":"1996","unstructured":"Baron, J. et al. Mutations in the Ca2+-sensing receptor gene cause autosomal dominant and sporadic hypoparathyroidism. Hum. Mol. Genet. 5, 601\u2013606 (1996).","journal-title":"Hum. Mol. Genet."},{"key":"1075_CR61","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1056\/NEJM199610103351505","volume":"335","author":"SH Pearce","year":"1996","unstructured":"Pearce, S. H. et al. A familial syndrome of hypocalcemia with hypercalciuria due to mutations in the calcium-sensing receptor. N. Engl. J. Med. 335, 1115\u20131122 (1996).","journal-title":"N. Engl. J. Med."},{"key":"1075_CR62","doi-asserted-by":"crossref","first-page":"1215036","DOI":"10.3389\/fendo.2023.1215036","volume":"14","author":"DS Ali","year":"2023","unstructured":"Ali, D. S. et al. Case report: calcium sensing receptor gene gain of function mutations: a case series and report of 2 novel mutations. Front. Endocrinol. 14, 1215036 (2023).","journal-title":"Front. Endocrinol."},{"key":"1075_CR63","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000687","volume":"8","author":"R Dadu","year":"2020","unstructured":"Dadu, R. et al. Calcium-sensing receptor autoantibody-mediated hypoparathyroidism associated with immune checkpoint inhibitor therapy: diagnosis and long-term follow-up. J. Immunother. Cancer 8, e000687 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"1075_CR64","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1210\/jc.2018-01151","volume":"104","author":"P Piranavan","year":"2019","unstructured":"Piranavan, P., Li, Y., Brown, E., Kemp, E. H. & Trivedi, N. Immune checkpoint inhibitor-induced hypoparathyroidism associated with calcium-sensing receptor-activating autoantibodies. J. Clin. Endocrinol. Metab. 104, 550\u2013556 (2019).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1075_CR65","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/0002-9610(89)90006-8","volume":"154","author":"GA Glazebrook","year":"1987","unstructured":"Glazebrook, G. A. Effect of decicurie doses of radioactive iodine 131 on parathyroid function. Am. J. Surg. 154, 368\u2013373 (1987).","journal-title":"Am. J. Surg."},{"key":"1075_CR66","doi-asserted-by":"crossref","first-page":"820","DOI":"10.2169\/internalmedicine.31.820","volume":"31","author":"S Mori","year":"1992","unstructured":"Mori, S. et al. Hypomagnesemia with increased metabolism of parathyroid hormone and reduced responsiveness to calcitropic hormones. Intern. Med. 31, 820\u2013824 (1992).","journal-title":"Intern. Med."},{"key":"1075_CR67","doi-asserted-by":"crossref","unstructured":"Khan, A. A., Sbayi, A. & Schlingmann, K. P. inPrimer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 9th edn (ed. Bilezikian, J. P.) Ch. 23, 173\u2013178 (Wiley-Blackwell, 2018).","DOI":"10.1002\/9781119266594.ch23"},{"key":"1075_CR68","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1097\/00041552-200207000-00006","volume":"11","author":"T Vetter","year":"2002","unstructured":"Vetter, T. & Lohse, M. J. Magnesium and the parathyroid. Curr. Opin. Nephrol. Hypertens. 11, 403\u2013410 (2002).","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"1075_CR69","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1053\/j.ajkd.2023.10.017","volume":"83","author":"EA Adomako","year":"2024","unstructured":"Adomako, E. A. & Yu, A. S. L. Magnesium disorders: core curriculum 2024. Am. J. Kidney Dis. 83, 803\u2013815 (2024).","journal-title":"Am. J. Kidney Dis."},{"key":"1075_CR70","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1016\/j.burns.2018.04.014","volume":"44","author":"E Schryver","year":"2018","unstructured":"Schryver, E. et al. Bone metabolism in pediatric burned patients: a review. Burns 44, 1863\u20131869 (2018).","journal-title":"Burns"},{"key":"1075_CR71","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1097\/MLG.0b013e318180276f","volume":"118","author":"MT Truong","year":"2008","unstructured":"Truong, M. T., Lalakea, M. L., Robbins, P. & Friduss, M. Primary hyperparathyroidism in pregnancy: a case series and review. Laryngoscope 118, 1966\u20131969 (2008).","journal-title":"Laryngoscope"},{"key":"1075_CR72","first-page":"438","volume":"55","author":"U \u00c7ak\u0131r","year":"2013","unstructured":"\u00c7ak\u0131r, U. et al. Late neonatal hypocalcemic tetany as a manifestation of unrecognized maternal primary hyperparathyroidism. Turk. J. Pediatr. 55, 438\u2013440 (2013).","journal-title":"Turk. J. Pediatr."},{"key":"1075_CR73","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1177\/0194599814555850","volume":"151","author":"CR Razavi","year":"2014","unstructured":"Razavi, C. R., Charitou, M. & Marzouk, M. Maternal atypical parathyroid adenoma as a cause of newborn hypocalcemic tetany. Otolaryngol. Head Neck Surg. 151, 1084\u20131085 (2014).","journal-title":"Otolaryngol. Head Neck Surg."},{"key":"1075_CR74","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1177\/000992280504400312","volume":"44","author":"A Alikasifoglu","year":"2005","unstructured":"Alikasifoglu, A., Gonc, E. N., Yalcin, E., Dogru, D. & Yordam, N. Neonatal hyperparathyroidism due to maternal hypoparathyroidism and vitamin D deficiency: a cause of multiple bone fractures. Clin. Pediatr. 44, 267\u2013269 (2005).","journal-title":"Clin. Pediatr."},{"key":"1075_CR75","doi-asserted-by":"crossref","first-page":"159","DOI":"10.6065\/apem.2346096.048","volume":"28","author":"HA Korkmaz","year":"2023","unstructured":"Korkmaz, H. A. & Ozkan, B. Hypoparathyroidism in children and adolescents. Ann. Pediatr. Endocrinol. Metab. 28, 159\u2013167 (2023).","journal-title":"Ann. Pediatr. Endocrinol. Metab."},{"key":"1075_CR76","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.21037\/gs.2017.10.04","volume":"6","author":"A Sitges-Serra","year":"2017","unstructured":"Sitges-Serra, A. et al. A nomogram to predict the likelihood of permanent hypoparathyroidism after total thyroidectomy based on delayed serum calcium and iPTH measurements. Gland. Surg. 6, S11\u2013S19 (2017).","journal-title":"Gland. Surg."},{"key":"1075_CR77","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1210\/jc.2015-3909","volume":"101","author":"DM Shoback","year":"2016","unstructured":"Shoback, D. M. et al. Presentation of hypoparathyroidism: etiologies and clinical features. J. Clin. Endocrinol. Metab. 101, 2300\u20132312 (2016).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1075_CR78","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1007\/s00268-019-04987-z","volume":"43","author":"G Ponce de Le\u00f3n-Ballesteros","year":"2019","unstructured":"Ponce de Le\u00f3n-Ballesteros, G. et al. Hypoparathyroidism after total thyroidectomy: importance of the intraoperative management of the parathyroid glands. World J. Surg. 43, 1728\u20131735 (2019).","journal-title":"World J. Surg."},{"key":"1075_CR79","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.ecl.2018.07.005","volume":"47","author":"HS Kazaure","year":"2018","unstructured":"Kazaure, H. S. & Sosa, J. A. Surgical hypoparathyroidism. Endocrinol. Metab. Clin. North Am. 47, 783\u2013796 (2018).","journal-title":"Endocrinol. Metab. Clin. North Am."},{"key":"1075_CR80","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.surg.2012.08.030","volume":"152","author":"AK Cayo","year":"2012","unstructured":"Cayo, A. K. et al. Predicting the need for calcium and calcitriol supplementation after total thyroidectomy: results of a prospective, randomized study. Surgery 152, 1059\u20131067 (2012).","journal-title":"Surgery"},{"key":"1075_CR81","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.jamcollsurg.2014.06.003","volume":"219","author":"AA Carr","year":"2014","unstructured":"Carr, A. A. et al. A single parathyroid hormone level obtained 4 hours after total thyroidectomy predicts the need for postoperative calcium supplementation. J. Am. Coll. Surg. 219, 757\u2013764 (2014).","journal-title":"J. Am. Coll. Surg."},{"key":"1075_CR82","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.surg.2012.03.011","volume":"152","author":"P Lecerf","year":"2012","unstructured":"Lecerf, P. et al. Parathyroid hormone decline 4 hours after total thyroidectomy accurately predicts hypocalcemia. Surgery 152, 863\u2013868 (2012).","journal-title":"Surgery"},{"key":"1075_CR83","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.1002\/jbmr.4673","volume":"37","author":"L Yao","year":"2022","unstructured":"Yao, L. et al. Complications, symptoms, presurgical predictors in patients with chronic hypoparathyroidism: a systematic review. J. Bone Miner. Res. 37, 2642\u20132653 (2022).","journal-title":"J. Bone Miner. Res."},{"key":"1075_CR84","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/cen.13895","volume":"90","author":"T Vadiveloo","year":"2019","unstructured":"Vadiveloo, T., Donnan, P. T., Leese, C. J., Abraham, K. J. & Leese, G. P. Increased mortality and morbidity in patients with chronic hypoparathyroidism: a population\u2010based study. Clin. Endocrinol. 90, 285\u2013292 (2019).","journal-title":"Clin. Endocrinol."},{"key":"1075_CR85","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1002\/jbmr.3368","volume":"33","author":"L Underbjerg","year":"2018","unstructured":"Underbjerg, L., Sikjaer, T. & Rejnmark, L. Long-term complications in patients with hypoparathyroidism evaluated by biochemical findings: a case-control study. J. Bone Miner. Res. 33, 822\u2013831 (2018).","journal-title":"J. Bone Miner. Res."},{"key":"1075_CR86","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s12020-021-02629-w","volume":"72","author":"AA Khan","year":"2021","unstructured":"Khan, A. A. et al. Canadian national hypoparathyroidism registry: an overview of hypoparathyroidism in Canada. Endocrine 72, 553\u2013561 (2021).","journal-title":"Endocrine"},{"key":"1075_CR87","doi-asserted-by":"crossref","first-page":"1244647","DOI":"10.3389\/fendo.2023.1244647","volume":"14","author":"K Gronemeyer","year":"2023","unstructured":"Gronemeyer, K. et al. Renal complications in chronic hypoparathyroidism \u2014 a systematic cross-sectional assessment. Front. Endocrinol. 14, 1244647 (2023).","journal-title":"Front. Endocrinol."},{"key":"1075_CR88","first-page":"1617","volume":"76","author":"S Abugassa","year":"1993","unstructured":"Abugassa, S., Nordenstr\u00f6m, J., Eriksson, S. & Sj\u00f6d\u00e9n, G. Bone mineral density in patients with chronic hypoparathyroidism. J. Clin. Endocrinol. Metab. 76, 1617\u20131621 (1993).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1075_CR89","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1172\/JCI110570","volume":"69","author":"E Seeman","year":"1982","unstructured":"Seeman, E. et al. Differential effects of endocrine dysfunction on the axial and the appendicular skeleton. J. Clin. Invest. 69, 1302\u20131309 (1982).","journal-title":"J. Clin. Invest."},{"key":"1075_CR90","doi-asserted-by":"crossref","first-page":"4655","DOI":"10.1210\/jc.2003-030470","volume":"88","author":"Q Chen","year":"2003","unstructured":"Chen, Q. et al. Effects of an excess and a deficiency of endogenous parathyroid hormone on volumetric bone mineral density and bone geometry determined by peripheral quantitative computed tomography in female subjects. J. Clin. Endocrinol. Metab. 88, 4655\u20134658 (2003).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1075_CR91","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s00198-016-3750-0","volume":"28","author":"BC Silva","year":"2017","unstructured":"Silva, B. C., Rubin, M. R., Cusano, N. E. & Bilezikian, J. P. Bone imaging in hypoparathyroidism. Osteoporos. Int. 28, 463\u2013471 (2017).","journal-title":"Osteoporos. Int."},{"key":"1075_CR92","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1359\/jbmr.080803","volume":"23","author":"MR Rubin","year":"2008","unstructured":"Rubin, M. R. et al. Dynamic and structural properties of the skeleton in hypoparathyroidism. J. Bone Miner. Res. 23, 2018\u20132024 (2008).","journal-title":"J. Bone Miner. Res."},{"key":"1075_CR93","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1002\/jbmr.2273","volume":"29","author":"L Underbjerg","year":"2014","unstructured":"Underbjerg, L., Sikjaer, T., Mosekilde, L. & Rejnmark, L. Postsurgical hypoparathyroidism-risk of fractures, psychiatric diseases, cancer, cataract, and infections. J. Bone Miner. Res. 29, 2504\u20132510 (2014).","journal-title":"J. Bone Miner. Res."},{"key":"1075_CR94","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1002\/jbmr.2501","volume":"30","author":"L Underbjerg","year":"2015","unstructured":"Underbjerg, L., Sikjaer, T., Mosekilde, L. & Rejnmark, L. The epidemiology of nonsurgical hypoparathyroidism in Denmark: a nationwide case finding study. J. Bone Miner. Res. 30, 1738\u20131744 (2015).","journal-title":"J. Bone Miner. Res."},{"key":"1075_CR95","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1007\/s00198-021-05966-8","volume":"32","author":"R Pal","year":"2021","unstructured":"Pal, R., Bhadada, S. K., Mukherjee, S., Banerjee, M. & Kumar, A. Fracture risk in hypoparathyroidism: a systematic review and meta-analysis. Osteoporos. Int. 32, 2145\u20132153 (2021).","journal-title":"Osteoporos. Int."},{"key":"1075_CR96","doi-asserted-by":"crossref","first-page":"bvae163.505","DOI":"10.1210\/jendso\/bvae163.505","volume":"8","author":"H AbuAlrob","year":"2024","unstructured":"AbuAlrob, H. et al. 8749 Skeletal effects among pre and postmenopausal women with hypoparathyroidism (HypoPT); data from the Canadian National Hypoparathyroidism Registry (CNHR). J. Endocr. Soc. 8, bvae163.505 (2024).","journal-title":"J. Endocr. Soc."},{"key":"1075_CR97","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1210\/clinem\/dgab076","volume":"106","author":"C Cipriani","year":"2021","unstructured":"Cipriani, C. et al. Vertebral fracture assessment in postmenopausal women with postsurgical hypoparathyroidism. J. Clin. Endocrinol. Metab. 106, 1303\u20131311 (2021).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1075_CR98","doi-asserted-by":"crossref","DOI":"10.1186\/1472-6823-13-1","volume":"13","author":"ML Mendon\u00e7a","year":"2013","unstructured":"Mendon\u00e7a, M. L. et al. Increased vertebral morphometric fracture in patients with postsurgical hypoparathyroidism despite normal bone mineral density. BMC Endocr. Disord. 13, 1 (2013).","journal-title":"BMC Endocr. Disord."},{"key":"1075_CR99","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1007\/s11914-023-00790-x","volume":"21","author":"L Rejnmark","year":"2023","unstructured":"Rejnmark, L. & Underbjerg, L. Fracture risk in patients with hypoparathyroidism. Curr. Osteoporos. Rep. 21, 632\u2013636 (2023).","journal-title":"Curr. Osteoporos. Rep."},{"key":"1075_CR100","doi-asserted-by":"crossref","first-page":"122","DOI":"10.15420\/aer.2019.8.3","volume":"8","author":"N El-Sherif","year":"2019","unstructured":"El-Sherif, N., Turitto, G. & Boutjdir, M. Acquired long QT syndrome and electrophysiology of torsade de pointes. Arrhythm. Electrophysiol. Rev. 8, 122\u2013130 (2019).","journal-title":"Arrhythm. Electrophysiol. Rev."},{"key":"1075_CR101","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S1388-9842(01)00125-8","volume":"3","author":"NG Fisher","year":"2001","unstructured":"Fisher, N. G., Armitage, A., McGonigle, R. J. & Gilbert, T. J. Hypocalcaemic cardiomyopathy; the relationship between myocardial damage, left ventricular function, calcium and ECG changes in a patient with idiopathic hypocalcaemia. Eur. J. Heart Fail. 3, 373\u2013376 (2001).","journal-title":"Eur. J. Heart Fail."},{"key":"1075_CR102","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1159\/000515985","volume":"147","author":"JKK Tang","year":"2022","unstructured":"Tang, J. K. K. & Rabkin, S. W. Hypocalcemia-induced QT interval prolongation. Cardiology 147, 191\u2013195 (2022).","journal-title":"Cardiology"},{"key":"1075_CR103","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1002\/ccr3.2397","volume":"7","author":"J De Oliveira Martins Duarte","year":"2019","unstructured":"De Oliveira Martins Duarte, J. et al. A rare and reversible case of heart failure \u2014 hypocalcemia due to hypoparathyroidism. Clin. Case Rep. 7, 1932\u20131934 (2019).","journal-title":"Clin. Case Rep."},{"key":"1075_CR104","volume":"15","author":"SH Kim","year":"2020","unstructured":"Kim, S. H. et al. Prevalence and complications of nonsurgical hypoparathyroidism in Korea: a nationwide cohort study. PLoS ONE\u00a015, e0232842 (2020).","journal-title":"PLoS ONE"},{"key":"1075_CR105","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1002\/jbmr.4698","volume":"37","author":"S Van Uum","year":"2022","unstructured":"Van Uum, S. et al. Initial assessment and monitoring of patients with chronic hypoparathyroidism: a systematic current practice survey. J. Bone Miner. Res. 37, 2630\u20132641 (2022).","journal-title":"J. Bone Miner. Res."},{"key":"1075_CR106","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1002\/jbmr.4716","volume":"37","author":"AA Khan","year":"2022","unstructured":"Khan, A. A. et al. Management of hypoparathyroidism. J. Bone Miner. Res. 37, 2663\u20132677 (2022). The most recent guidelines on the management of hypoparathyroidism, which also include a section on pregnant and lactating patients.","journal-title":"J. Bone Miner. Res."},{"key":"1075_CR107","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1210\/jc.2015-3910","volume":"101","author":"JP Bilezikian","year":"2016","unstructured":"Bilezikian, J. P. et al. Management of hypoparathyroidism: present and future. J. Clin. Endocrinol. Metab. 101, 2313\u20132324 (2016).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1075_CR108","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1056\/NEJM198708273170903","volume":"317","author":"MS Sheikh","year":"1987","unstructured":"Sheikh, M. S., Santa Ana, C. A., Nicar, M. J., Schiller, L. R. & Fordtran, J. S. Gastrointestinal absorption of calcium from milk and calcium salts. N. Engl. J. Med. 317, 532\u2013536 (1987).","journal-title":"N. Engl. J. Med."},{"key":"1075_CR109","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1056\/NEJM198904273201703","volume":"320","author":"LR Schiller","year":"1989","unstructured":"Schiller, L. R., Santa Ana, C. A., Sheikh, M. S., Emmett, M. & Fordtran, J. S. Effect of the time of administration of calcium acetate on phosphorus binding. N. Engl. J. Med. 320, 1110\u20131113 (1989).","journal-title":"N. Engl. J. Med."},{"key":"1075_CR110","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.pbiomolbio.2006.02.016","volume":"92","author":"P Lips","year":"2006","unstructured":"Lips, P. Vitamin D physiology. Prog. Biophys. Mol. Biol. 92, 4\u20138 (2006).","journal-title":"Prog. Biophys. Mol. Biol."},{"key":"1075_CR111","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1007\/s11154-021-09693-7","volume":"22","author":"JP Bilezikian","year":"2021","unstructured":"Bilezikian, J. P. et al. Vitamin D: dosing, levels, form, and route of administration: does one approach fit all? Rev. Endocr. Metab. Disord. 22, 1201\u20131218 (2021).","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"1075_CR112","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1210\/endrev\/bnae009","volume":"45","author":"A Giustina","year":"2024","unstructured":"Giustina, A. et al. Consensus statement on vitamin D status assessment and supplementation: whys, whens, and hows. Endocr. Rev. 45, 625\u2013654 (2024).","journal-title":"Endocr. Rev."},{"key":"1075_CR113","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1210\/jc.2011-0385","volume":"96","author":"MF Holick","year":"2011","unstructured":"Holick, M. F. et al. Evaluation, treatment, and prevention of vitamin D deficiency: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 96, 1911\u20131930 (2011).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1075_CR114","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1056\/NEJM197803162981101","volume":"298","author":"RH Porter","year":"1978","unstructured":"Porter, R. H. et al. Treatment of hypoparathyroid patients with chlorthalidone. N. Engl. J. Med. 298, 577\u2013581 (1978).","journal-title":"N. Engl. J. Med."},{"key":"1075_CR115","doi-asserted-by":"crossref","first-page":"4507","DOI":"10.1210\/jc.2012-1808","volume":"97","author":"DM Mitchell","year":"2012","unstructured":"Mitchell, D. M. et al. Long-term follow-up of patients with hypoparathyroidism. J. Clin. Endocrinol. Metab. 97, 4507\u20134514 (2012).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1075_CR116","first-page":"OC13.5","volume":"99","author":"MH Schernthaner-Reiter","year":"2024","unstructured":"Schernthaner-Reiter, M. H. et al. Use of thiazide diuretics in hypoparathyroidism: indication and effects. Endocr. Abstr. 99, OC13.5 (2024).","journal-title":"Endocr. Abstr."},{"key":"1075_CR117","volume":"20","author":"SC Shao","year":"2022","unstructured":"Shao, S. C. et al. Associations of thiazide use with skin cancers: a systematic review and meta-analysis. BMC Med. 20, 228 (2022).","journal-title":"BMC Med."},{"key":"1075_CR118","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1097\/HJH.0000000000002136","volume":"37","author":"R Kreutz","year":"2019","unstructured":"Kreutz, R., Algharably, E. A. H. & Douros, A. Reviewing the effects of thiazide and thiazide-like diuretics as photosensitizing drugs on the risk of skin cancer. J. Hypertens. 37, 1950\u20131958 (2019).","journal-title":"J. Hypertens."},{"key":"1075_CR119","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.mayocp.2022.12.002","volume":"98","author":"MH Rosner","year":"2023","unstructured":"Rosner, M. H., Ha, N., Palmer, B. F. & Perazella, M. A. Acquired disorders of hypomagnesemia. Mayo Clin. Proc. 98, 581\u2013596 (2023).","journal-title":"Mayo Clin. Proc."},{"key":"1075_CR120","doi-asserted-by":"crossref","first-page":"115977","DOI":"10.1016\/j.bone.2021.115977","volume":"149","author":"KK Winer","year":"2021","unstructured":"Winer, K. K. et al. Therapy with PTH 1-34 or calcitriol and calcium in diverse etiologies of hypoparathyroidism over 27 years at a single tertiary care center. Bone 149, 115977 (2021).","journal-title":"Bone"},{"key":"1075_CR121","unstructured":"US Food and Drug Administration. Forteo (teriparatide) NDA approval letter and labeling. accessdata.fda.gov https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2002\/21-318_Forteo.cfm (2002)."},{"key":"1075_CR122","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.eprac.2023.12.001","volume":"30","author":"MR Rubin","year":"2024","unstructured":"Rubin, M. R. et al. Extended treatment with recombinant human parathyroid hormone (1-84) in adult patients with chronic hypoparathyroidism. Endocr. Pract. 30, 200\u2013208 (2024).","journal-title":"Endocr. Pract."},{"key":"1075_CR123","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1002\/jbmr.4566","volume":"37","author":"G Puliani","year":"2022","unstructured":"Puliani, G. et al. Safety and efficacy of PTH 1-34 and 1-84 therapy in chronic hypoparathyroidism: a meta-analysis of prospective trials. J. Bone Miner. Res. 37, 1233\u20131250 (2022).","journal-title":"J. Bone Miner. Res."},{"key":"1075_CR124","doi-asserted-by":"crossref","first-page":"e372","DOI":"10.1210\/clinem\/dgab577","volume":"107","author":"AA Khan","year":"2022","unstructured":"Khan, A. A. et al. Path forward: a randomized, double-blind, placebo-controlled phase 2 trial of transcon PTH in adult hypoparathyroidism. J. Clin. Endocrinol. Metab. 107, e372\u2013e385 (2022).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1075_CR125","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1002\/jbmr.4016","volume":"35","author":"DB Karpf","year":"2020","unstructured":"Karpf, D. B. et al. A randomized double-blind placebo-controlled first-in-human phase 1 trial of TransCon PTH in healthy adults. J. Bone Miner. Res. 35, 1430\u20131440 (2020).","journal-title":"J. Bone Miner. Res."},{"key":"1075_CR126","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/jbmr.4726","volume":"38","author":"AA Khan","year":"2023","unstructured":"Khan, A. A. et al. Efficacy and safety of parathyroid hormone replacement with transcon PTH in hypoparathyroidism: 26-week results from the phase 3 PaTHway trial. J. Bone Miner. Res. 38, 14\u201325 (2023). An important trial for the safety and efficacy of palopegteriparatide.","journal-title":"J. Bone Miner. Res."},{"key":"1075_CR127","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1007\/s12325-024-02843-8","volume":"41","author":"L Rejnmark","year":"2024","unstructured":"Rejnmark, L. et al. Palopegteriparatide treatment improves renal function in adults with chronic hypoparathyROIDISM: 1-year results from the phase 3 PaTHway trial. Adv. Ther. 41, 2500\u20132518 (2024).","journal-title":"Adv. Ther."},{"key":"1075_CR128","first-page":"PLO14","volume":"8","author":"AA Khan","year":"2024","unstructured":"Khan, A. A. et al. Abstracts of the ECTS 2024 congress: improved skeletal dynamics in adults treated with palopegteriparatide (TransCon PTH) for hypoparathyroidism: 52-week analysis of phase 3 PaTHway trial. J. Bone Miner. Res. 8, PLO14 (2024).","journal-title":"J. Bone Miner. Res."},{"key":"1075_CR129","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1002\/jbmr.2811","volume":"31","author":"M Shimizu","year":"2016","unstructured":"Shimizu, M. et al. Pharmacodynamic actions of a long-acting PTH analog (LA-PTH) in thyroparathyroidectomized (TPTX) rats and normal monkeys. J. Bone Miner. Res. 31, 1405\u20131412 (2016).","journal-title":"J. Bone Miner. Res."},{"key":"1075_CR130","doi-asserted-by":"crossref","first-page":"A254","DOI":"10.1210\/jendso\/bvab048.516","volume":"5","author":"S Allas","year":"2021","unstructured":"Allas, S. et al. A single administration of AZP-3601, a novel, long-acting pth analog, induces a significant and sustained calcemic response: preliminary data from a randomized, double-blind, placebo-controlled phase 1 study. J. Endocr. Soc. 5, A254 (2021).","journal-title":"J. Endocr. Soc."},{"key":"1075_CR131","volume":"4","author":"H Noda","year":"2020","unstructured":"Noda, H. et al. Optimization of PTH\/PTHrP hybrid peptides to derive a long-acting PTH analog (LA-PTH). J. Bone Miner. Res. 4, e10367 (2020).","journal-title":"J. Bone Miner. Res."},{"key":"1075_CR132","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1210\/en.2015-1726","volume":"157","author":"G Hattersley","year":"2016","unstructured":"Hattersley, G., Dean, T., Corbin, B. A., Bahar, H. & Gardella, T. J. Binding selectivity of abaloparatide for PTH-type-1-receptor conformations and effects on downstream signaling. Endocrinology 157, 141\u2013149 (2016).","journal-title":"Endocrinology"},{"key":"1075_CR133","doi-asserted-by":"crossref","first-page":"4083","DOI":"10.1111\/bph.14086","volume":"175","author":"FM Hannan","year":"2018","unstructured":"Hannan, F. M., Olesen, M. K. & Thakker, R. V. Calcimimetic and calcilytic therapies for inherited disorders of the calcium-sensing receptor signalling pathway. Br. J. Pharmacol. 175, 4083\u20134094 (2018).","journal-title":"Br. J. Pharmacol."},{"key":"1075_CR134","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1002\/jbmr.3747","volume":"34","author":"MS Roberts","year":"2019","unstructured":"Roberts, M. S. et al. Treatment of autosomal dominant hypocalcemia type 1 with the calcilytic NPSP795 (SHP635). J. Bone Miner. Res. 34, 1609\u20131618 (2019).","journal-title":"J. Bone Miner. Res."},{"key":"1075_CR135","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1152\/physrev.00027.2015","volume":"96","author":"CS Kovacs","year":"2016","unstructured":"Kovacs, C. S. Maternal mineral and bone metabolism during pregnancy, lactation, and post-weaning recovery. Physiol. Rev. 96, 449\u2013547 (2016). An excellent review of bone metabolism in pregnancy and postpartum patients.","journal-title":"Physiol. Rev."},{"key":"1075_CR136","doi-asserted-by":"crossref","first-page":"R37","DOI":"10.1530\/EJE-18-0541","volume":"180","author":"AA Khan","year":"2019","unstructured":"Khan, A. A., Clarke, B., Rejnmark, L. & Brandi, M. L. Management of endocrine disease: hypoparathyroidism in pregnancy: review and evidence-based recommendations for management. Eur. J. Endocrinol. 180, R37\u2013R44 (2019).","journal-title":"Eur. J. Endocrinol."},{"key":"1075_CR137","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.3390\/jcm10071378","volume":"10","author":"DS Ali","year":"2021","unstructured":"Ali, D. S., Dandurand, K. & Khan, A. A. Hypoparathyroidism in pregnancy and lactation: current approach to diagnosis and management. J. Clin. Med. 10, 1378 (2021).","journal-title":"J. Clin. Med."},{"key":"1075_CR138","doi-asserted-by":"crossref","first-page":"393","DOI":"10.3109\/00016349409006250","volume":"73","author":"T Dahlman","year":"1994","unstructured":"Dahlman, T., Sj\u00f6berg, H. E. & Bucht, E. Calcium homeostasis in normal pregnancy and puerperium. A longitudinal study. Acta Obstet. Gynecol. Scand. 73, 393\u2013398 (1994).","journal-title":"Acta Obstet. Gynecol. Scand."},{"key":"1075_CR139","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/0002-9378(91)90694-M","volume":"164","author":"K Seki","year":"1991","unstructured":"Seki, K., Makimura, N., Mitsui, C., Hirata, J. & Nagata, I. Calcium-regulating hormones and osteocalcin levels during pregnancy: a longitudinal study. Am. J. Obstet. Gynecol. 164, 1248\u20131252 (1991).","journal-title":"Am. J. Obstet. Gynecol."},{"key":"1075_CR140","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1530\/eje.0.1370402","volume":"137","author":"MS Ardawi","year":"1997","unstructured":"Ardawi, M. S., Nasrat, H. A. & HS, B. A. A. Calcium-regulating hormones and parathyroid hormone-related peptide in normal human pregnancy and postpartum: a longitudinal study. Eur. J. Endocrinol. 137, 402\u2013409 (1997).","journal-title":"Eur. J. Endocrinol."},{"key":"1075_CR141","doi-asserted-by":"crossref","unstructured":"Kovacs, C. S., Chakhtoura, M. & Fuleihan, G. E.-H. in Maternal-Fetal and Neonatal Endocrinology (eds Kovacs, C. S. & Deal, C. L.) Ch. 21, 329\u2013370 (Elsevier, 2020).","DOI":"10.1016\/B978-0-12-814823-5.00021-0"},{"key":"1075_CR142","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/cen.14212","volume":"93","author":"EAR Hartogsohn","year":"2020","unstructured":"Hartogsohn, E. A. R. et al. Changes in treatment needs of hypoparathyroidism during pregnancy and lactation: a case series. Clin. Endocrinol. 93, 261\u2013268 (2020).","journal-title":"Clin. Endocrinol."},{"key":"1075_CR143","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1210\/jcem-26-5-487","volume":"26","author":"T Aceto Jr.","year":"1966","unstructured":"Aceto, T. Jr., Batt, R. E., Bruck, E., Schultz, R. B. & Perz, Y. R. Intrauterine hyperparathyroidism: a complication of untreated maternal hypoparathyroidism. J. Clin. Endocrinol. Metab. 26, 487\u2013492 (1966).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1075_CR144","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1542\/peds.42.4.606","volume":"42","author":"D Bronsky","year":"1968","unstructured":"Bronsky, D., Kiamko, R. T., Moncada, R. & Rosenthal, I. M. Intra-uterine hyperparathyroidism secondary to maternal hypoparathyroidism. Pediatrics 42, 606\u2013613 (1968).","journal-title":"Pediatrics"},{"key":"1075_CR145","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1179\/146532809X440770","volume":"29","author":"N Demirel","year":"2009","unstructured":"Demirel, N. et al. Hyperparathyroidism secondary to maternal hypoparathyroidism and vitamin D deficiency: an uncommon cause of neonatal respiratory distress. Ann. Trop. Paediatr. 29, 149\u2013154 (2009).","journal-title":"Ann. Trop. Paediatr."},{"key":"1075_CR146","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.pediatrneurol.2013.02.010","volume":"48","author":"JF Borkenhagen","year":"2013","unstructured":"Borkenhagen, J. F., Connor, E. L. & Stafstrom, C. E. Neonatal hypocalcemic seizures due to excessive maternal calcium ingestion. Pediatr. Neurol. 48, 469\u2013471 (2013).","journal-title":"Pediatr. Neurol."},{"key":"1075_CR147","first-page":"410.e1-5","volume":"199","author":"H Shani","year":"2008","unstructured":"Shani, H., Sivan, E., Cassif, E. & Simchen, M. J. Maternal hypercalcemia as a possible cause of unexplained fetal polyhydramnion: a case series. Am. J. Obstet. Gynecol. 199, 410.e1-5 (2008).","journal-title":"Am. J. Obstet. Gynecol."},{"key":"1075_CR148","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.siny.2003.10.002","volume":"9","author":"SC Hsu","year":"2004","unstructured":"Hsu, S. C. & Levine, M. A. Perinatal calcium metabolism: physiology and pathophysiology. Semin. Neonatol. 9, 23\u201336 (2004).","journal-title":"Semin. Neonatol."},{"key":"1075_CR149","doi-asserted-by":"crossref","unstructured":"Goodman, H. M. In: Basic Medical Endocrinology Fourth Edition Ch. 10 (ed. Goodman, H. M.) 197-218 (Elsevier, 2009).","DOI":"10.1016\/B978-0-12-373975-9.00010-0"},{"key":"1075_CR150","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41574-018-0115-0","volume":"15","author":"FM Hannan","year":"2018","unstructured":"Hannan, F. M., Kallay, E., Chang, W., Brandi, M. L. & Thakker, R. V. The calcium-sensing receptor in physiology and in calcitropic and noncalcitropic diseases. Nat. Rev. Endocrinol. 15, 33\u201351 (2018).","journal-title":"Nat. Rev. Endocrinol."},{"key":"1075_CR151","doi-asserted-by":"crossref","unstructured":"Thakker R. V., Bringhurst F. R. & J\u00fcppner H. in Endocrinology, 7th edn (eds.\u00a0De Groot L. J. & Jameson, J. L.) 1063\u20131089 (Elsevier, 2016).","DOI":"10.1016\/B978-0-323-18907-1.00061-5"}],"container-title":["Nature Reviews Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41574-024-01075-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41574-024-01075-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41574-024-01075-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:03:17Z","timestamp":1747353797000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41574-024-01075-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,4]]},"references-count":151,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["1075"],"URL":"https:\/\/doi.org\/10.1038\/s41574-024-01075-8","relation":{},"ISSN":["1759-5029","1759-5037"],"issn-type":[{"value":"1759-5029","type":"print"},{"value":"1759-5037","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,4]]},"assertion":[{"value":"29 November 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.K. is primary investigator for trials funded by Ascendis, Amolyt, Calcilytix and Alexion. S.K. has received honoraria and served on advisory boards for Amgen Pharmaceuticals and Sandoz Pharmaceuticals. She is a co-investigator for trials funded by Calcilytix and Ascendis. She is a primary investigator for a trial funded by Ultragenyx.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}